Publications

Want to be in the know about the latest advances in diabetes research? Need more information on how to live well with T1D? Connect with us on social networking sites, subscribe to our emails, and check out our print and online materials.



Countdown

  • Improving Beta Cell Health and Survival

    JDRF-funded clinical study to test marketed drug to improve beta cell health and survival in T1D JDRF recently awarded a $2.1 million grant to Anath Shalev, M.D., director of the University of Alabama’s (UAB) Comprehensive Diabetes Center, to test the impact of a common blood pressure drug called verapamil on the health and survival of […]

    Read More

  • Historic Progress for JDRF Encapsulation Research Program

    First people with type 1 diabetes receive experimental encapsulated cell replacement therapies in clinical studies Two JDRF-funded partners have successfully implanted people with type 1 diabetes (T1D) with experimental encapsulated cell replacement therapies in clinical studies. These two programs are running in parallel and are evaluating two distinct encapsulation therapies. Encapsulated cell replacement therapy involves […]

    Read More

  • A Personal Story: The Need for Medicare Coverage of Continuous Glucose Monitors (CGM)

    Diabetes technologies have the potential to transform the care of people with diabetes. The continuous glucose monitor (CGM) has been shown to improve glucose control—preventing dangerous high and low blood sugars—and is recommended by national diabetes clinical guidelines and covered by private health plans. However, Medicare does not yet cover CGM devices, denying Americans age […]

    Read More

  • It’s Time to Redefine Type 1 Diabetes

    JDRF helped to organize a conference to define the stages and discuss how type 1 diabetes progresses Last month, JDRF co-hosted a workshop where healthcare experts from government, nonprofit agencies and educational institutions discussed expanding the definition of Type 1 Diabetes (T1D) to recognize the earliest stages of human T1D before a person is clinically […]

    Read More

  • Making the T1D Vaccine a Reality

    Nanoparticle-based vaccine is designed to re-educate the immune system and halt the attack on the pancreas Over the last three years, Selecta Bioscience, a clinical stage biotechnology company, has been developing nanoparticles called Synthetic Vaccine Particle (SVP) as an immunotherapy for Type 1 diabetes (T1D) with support from JDRF and it was announced this week […]

    Read More